JNJ at a glance
Johnson & Johnson (JNJ, SEC CIK 200406) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 13, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03.
- As of September 30, 2026, 73 institutional investment managers tracked by SignalX reported holding Johnson & Johnson (JNJ) shares worth $238.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Forminard Elizabeth on November 12, 2026 of 13,072 shares at $284.39 per share.
- In the last 90 days, JNJ insiders reported 0 open-market purchases ($0) and 3 open-market sales ($12.9M) on Form 4, a net sale of $12.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $94.2B
- +6.0% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$12.9M
- 13F holders
- 73 funds
- $238.7B · −3 vs prior quarter
- Latest 8-K
- Oct 13, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Business Overview
- New emphasis on transparency with online posting of Code of Business Conduct amendments and waivers within five business days
- Strengthened insider trading policy for directors, officers, and certain insiders to ensure compliance with laws and listing standards
- Unusual focus on detailed disclosure of corporate governance codes and ethical standards rather than product or market information
Management Discussion & Analysis
- Revenue $94.2B in 2025, up 6.0% YoY from $88.8B in 2024; U.S. sales $53.8B (+6.9%), international $40.4B (+5.0%)
- Operating margin 34.6% in 2025 vs 18.8% in 2024; Innovative Medicine margin 36.9% vs 33.2%; MedTech margin 12.2% vs 11.7%
- Best segment: Innovative Medicine sales $60.4B (+6.0%), worst: Infectious Diseases sales $3.2B (-4.6%)
- Cash/cash equivalents $20.1B end 2025; total debt $47.9B; acquisitions funded with senior notes; restructuring costs $205M (Surgery), $307M (Orthopaedics)
- Risks: biosimilar competition impacting STELARA; expected generic competition for OPSUMIT in 2026; planned Orthopaedics separation in 18-24 months
Risk Factors
- Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws
- CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry
- CIO and CISO responsible for cybersecurity incident detection, response, and recovery with 25+ years CISO experience
- Cybersecurity risk management integrated into overall risk framework, with emphasis on threats relevant to 2026 landscape
AI summary of the JNJ 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 27, 2026
Management Discussion & Analysis
- Emerging risks: pricing pressure, patent expirations, litigation, tariffs, supply-chain disruptions
- Planned Orthopaedics separation: timing, execution, and anticipated benefits remain uncertain
AI summary of the JNJ 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026
- Investor-relevant financial details contained in attached Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 sales $25.4B, up 5.9%, with operational growth 6.0%, led by Innovative Medicine growth of 7.9%
- GAAP EPS $0.09 versus $2.12, reflecting special charges tied to talc litigation, Firefly Bio, and Sail Biomedicines
Item EX-99.2: Item EX-99.2
- Q3 worldwide sales $25,399M, up 5.9%, with operational growth 6.0% and U.S. growth 9.1%
- Innovative Medicine sales $16,757M, up 7.7%, led by Oncology growth 16.4% and Tremfya growth 68.3%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine
- Departure also removes Taubert from Johnson & Johnson’s Executive Committee
Item EX-99.1: Item EX-99.1
- Completed Firefly Bio acquisition for $1 billion cash, expanding J&J’s oncology platform into pan-KRAS and other difficult-to-treat cancers
- Firelink™ degrader antibody conjugate platform enables targeted protein degradation, supporting next-generation solid-tumor therapies
Item 7.01: Regulation FD Disclosure
- Firefly acquisition completed and Sail strategic collaboration signed, marking expanded investment in biotech pipeline
- 2026 adjusted EPS guidance reduced $0.64 to $10.96–$11.11, with transactions cutting adjusted operational EPS by $0.64
Item EX-99.2: Item EX-99.2
- Strategic collaboration with Sail to advance in vivo CAR-T programs targeting immune-mediated diseases and immune-system reset
- Initial payments $785 million, including $465 million equity investment, plus $140 million contingent development milestones
AI summaries of JNJ 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JNJ
Don't miss the next JNJ filing
- Alerts as it files. A push when JNJ files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JNJ, by share count.
- Ask anything. An AI agent that reads every JNJ filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Forminard Elizabeth | M | Nov 12, 2026 | 13,072 | $151.41 |
| Forminard Elizabeth | Sell | Nov 12, 2026 | 13,072 | $284.39 |
| Forminard Elizabeth | M | Nov 12, 2026 | 13,072 | - |
| Pinto Daniel E | A | Sep 8, 2026 | 113.098 | $276.31 |
| Woods Eugene A. | A | Sep 8, 2026 | 135.717 | $276.31 |
| HEWSON MARILLYN A | A | Sep 8, 2026 | 180.956 | $276.31 |
| Schmid Timothy | M | Sep 2, 2026 | 11,070 | - |
| Schmid Timothy | M | Sep 2, 2026 | 22,527 | $151.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $88.8B | $94.2B |
| Gross Profit | $58.6B | $61.4B | $63.9B |
| Net Income | - | $14.1B | $26.8B |
| Gross Margin | - | 69.1% | 67.9% |
| Net Margin | - | 15.8% | 28.5% |
| Balance Sheet | |||
| Total Assets | $167.6B | $180.1B | $199.2B |
| Equity | - | $71.5B | $81.5B |
| ROE | - | 19.7% | 32.9% |
| Per Share | |||
| EPS | $13.72 | $5.79 | $11.03 |
| Cash Flow | |||
| Operating CF | $22.8B | $24.3B | $24.5B |
| CapEx | - | $4.4B | $4.8B |
Source: XBRL data in Johnson & Johnson (JNJ)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate JNJ share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 73 | $238.72B |
| Q2 2026 | 76 | $235.43B |
| Q1 2026 | 75 | $226.68B |
| Q4 2025 | 71 | $193.32B |
| Q3 2025 | 76 | $185.06B |
| Q2 2025 | 75 | $142.41B |
| Q1 2025 | 72 | $118.25B |
| Q4 2024 | 70 | $81.78B |
- JPMorgan Chase & Co+3.45M (+6%)
- Vanguard Portfolio Management LLC+1.28M (+2%)
- Citadel Advisors LLC+1.24M (+83%)
- Franklin Resources+861.7K (+9%)
- Vanguard Capital Management LLC+530.9K (+0%)
- Goldman Sachs Group−2.72M (-14%)
- BlackRock−2.38M (-1%)
- T. Rowe Price Group−1.05M (-5%)
- Invesco Ltd−693.5K (-4%)
- Bank of America Corp−649.7K (-3%)
- Blackstone Group+1.7K
- FMR LLC (Fidelity)−22.60M
- Equitable Holdings Inc−144.8K
- Ally Financial Inc−13.0K
- Northwest Bancshares, Inc.−9.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 588 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JNJ filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 13F-HR | Oct 26, 2026 | Sep 30, 2026 | - | - |
| 10-Q | Oct 21, 2026 | Sep 27, 2026 | Analysis | |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 13F-HR | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 28, 2026 | Analysis | |
| 4 | Jul 21, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 13F-HR | May 13, 2026 | Mar 31, 2026 | - | |
| 4 | May 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JNJ SEC filings: frequently asked questions
Are JNJ insiders buying or selling?
In the last 90 days, Johnson & Johnson (JNJ) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $12.9 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold JNJ stock?
As of September 30, 2026, the largest Johnson & Johnson (JNJ) holders among the 13F filers tracked by SignalX were BlackRock ($55.5 billion), Vanguard Capital Management LLC ($41.8 billion), State Street Corp ($35.5 billion), Vanguard Portfolio Management LLC ($17.4 billion), JPMorgan Chase & Co ($16.5 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was JNJ's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03. The figures come from the XBRL data in the 10-K.
What are the main risks in JNJ's latest 10-K?
In the 10-K filed February 11, 2026, Johnson & Johnson (JNJ) flagged: Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws. CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry. (AI summary of the Risk Factors section.)
What did JNJ report in its latest 8-K?
Johnson & Johnson (JNJ) filed an 8-K on October 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026.
What are the latest JNJ SEC filings?
Johnson & Johnson (JNJ) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 13, 2026 and a Form 4 insider filing on November 13, 2026.
What is JNJ's SEC CIK number?
Johnson & Johnson (JNJ)'s SEC Central Index Key (CIK) is 200406. EDGAR lists every JNJ filing under that number.
Ask anything about JNJ
The research agent reads JNJ's filings, financials, insider trades and 13F holders, then answers with sources.